Skip to main content

Adbry Disease Interactions

There are 3 disease interactions with Adbry (tralokinumab).

Moderate

Tralokinumab (applies to Adbry) live vaccines

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Vaccination

Tralokinumab may alter patient immunity and increase risk of infection after administration of live vaccines. Before starting this drug, complete all age-appropriate vaccinations according to current guidelines. Do not use live vaccines in patients treated tralokinumab.

Switch to professional interaction data

Moderate

Tralokinumab (applies to Adbry) parasitic infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Tralokinumab may influence the immune response against helminth infections by inhibiting interleukin 13 (IL-13) signaling. Patients with preexisting helminth infections should be treated before initiating treatment with this drug. If patients become infected while already in treatment and do not respond to antihelminth treatment, discontinue this drug until infection resolves.

Switch to professional interaction data

Moderate

Tralokinumab (applies to Adbry) visual disturbances

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance

Conjunctivitis and keratitis occurred more frequently in patients with atopic dermatitis who received tralokinmab, being conjunctivitis the most frequently reported eye disorder. Patients should report new onset or worsening of any existing eye symptoms to their healthcare provider.

Switch to professional interaction data

Adbry drug interactions

There are 23 drug interactions with Adbry (tralokinumab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer